Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Proactive Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$4,751,395

271 payments

Through program year 2025, Proactive Clinical Research LLC is reported as receiving $4,751,395 in research payments, across 271 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $527,666 44
2024 Research $1,802,505 52
2023 Research $1,217,615 148
2022 Research $1,203,609 27

Breakdown

Who paid Research payments · program years 2022–2025
  1. Pfizer Inc. $4,091,930 202 payments
  2. Bavarian Nordic A/S $398,354 45 payments
  3. Becton, Dickinson and Company $181,600 8 payments
  4. Amgen Inc. $24,386 1 payment
  5. AstraZeneca Pharmaceuticals LP $20,890 1 payment
  6. Ardelyx, Inc. $11,500 1 payment
  7. Teva Pharmaceuticals USA, Inc. $11,226 6 payments
  8. Esperion Therapeutics, Inc. $7,363 4 payments
  9. Ionis Pharmaceuticals, Inc. $4,148 3 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $2,355,007 60 payments
  2. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $485,229 19 payments
  3. A Phase 12 Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Varicella Zoster Virus in Healthy Individuals $354,487 25 payments
  4. A Phase 3 Multicenter Parallelgroup Openlabel Study to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine When Coadministered With Herpes Zoster Subunit Vaccine in Adults 50 Years of Age $334,056 9 payments
  5. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $305,829 44 payments
  6. A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $233,613 26 payments
  7. Maxmm2 $157,400 4 payments
  8. A Phase 2B Doubleblind Randomized Placebocontrolled Parallel Group Dose Ranging Study to Evaluate Virological Response and Safety of Oral Pf07817883 in Nonhospitalized Symptomatic Adult Participants With Covid19 $128,907 14 payments
  9. Nct05238025 $92,525 1 payment
  10. A Master Phase 123 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children $58,424 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record